Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 182

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 182
---
 the combined company to transfer technology or development. The transfer or license of IIA -supportedtechnology or know -howoutside of Israel and the transfer of manufacturing of IIA -supportedproducts, technology or know -howoutside of Israel may involve the payment of significant amounts, depending upon the value of the transferred or licensed technology or know -how, the combined company’s research and development expenses, the amount of IIA support, the time of completion of the IIA -supportedresearch project and availability of similar services in Israel and other factors. These restrictions and requirements for payment may impair its ability to sell, license or otherwise transfer its technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or technology outside of Israel. Furthermore, the consideration available to the combined company’s shareholders in a transaction involving the transfer outside of Israel of technology or know -howdeveloped with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that the combined company are required to pay to the IIA. The combined company may not be able to enforce covenants not-to-compete under current Israeli law that might result in added competition for its products. The combined company have non -competitionagreements with all of its employees, all of which are governed by Israeli law. These agreements prohibit the combined company employees from competing with or working for its competitors. However, Israeli courts are reluctant to enforce non -competeundertakings of former employees and tend, if at all, to enforce those provisions for relatively brief periods of time in restricted geographical areas, and only when the employee has obtained unique value to the employer specific to that employer’s business and not just regarding the professional development of the employee. If it is not able to enforce non -competecovenants, it may be faced with added competition. 73 EXTRAORDINARY SHAREHOLDER MEETING OF NLS General NLS is furnishing this proxy statement/prospectus to NLS’s shareholders as part of the solicitation of proxies by the NLS Board for use at the NLS Meeting to be held on, 2025, and at any adjournment thereof. This proxy statement/prospectus provides NLS’s shareholders with information they need to know to be able to vote or instruct their vote to be cast at the NLS Meeting. Date, Time and Place The NLS Meeting will be held on, 2025 ata.m./p.m., local time, at Advokatur 107, Rorschacher Str